1. Cereblon in health and disease
   Hyoung Kyu Kim et al, 2016, Pflügers Archiv - European Journal of Physiology CrossRef
2. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type
   Motoko Yamaguchi et al, 2018, Blood CrossRef
3. De-Novo Design of Cereblon (CRBN) Effectors Guided by Natural Hydrolysis Products of Thalidomide Derivatives
   Christopher Heim et al, 2019, Journal of Medicinal Chemistry CrossRef
4. Cereblon Deficiency Contributes to the Development of Elastase-Induced Emphysema by Enhancing NF-κB Activation
   Eun-Young Heo et al, 2022, Antioxidants CrossRef
5. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs
   Ota Fuchs, 2019, Cardiovascular & Hematological Disorders-Drug Targets CrossRef
6. Advances and challenges of immunotherapies in NK/T cell lymphomas
   Ling He et al, 2023, iScience CrossRef
7. Novel target and treatment agents for natural killer/T-cell lymphoma
   Xiao-Peng Tian et al, 2023, Journal of Hematology & Oncology CrossRef
8. The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T‐cell lymphoma with analysis of biomarkers
   Ling Li et al, 2017, British Journal of Haematology CrossRef
9. Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium
   Elżbieta Iskierka-Jażdżewska et al, 2020, Leukemia & Lymphoma CrossRef
10. Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms
    Hao Guo et al, 2022, Frontiers in Immunology CrossRef